Total raised
$137.0M
Last: Series B 2022-01
Stage
Acquired
Founded
2017
Headcount
49
HQ
Rehovot
Sector
Health Tech & Life Sciences
About
ImmPACT Bio is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients who have exhausted their treatment options. The company's logic-gate-based CAR T platforms address key biological challenges in treating cancer. ImmPACT Bio's technologies are specifically designed to prevent antigen escape, prevent "on-target off-tumor" toxicities, and overcome the immunosuppressive tumor microenvironment.
The company's technology is based on the work of Yvonne Chen, PhD, and Antoni Ribas, MD, PhD, both from University of California, Los Angeles, and Gideon Gross, PhD, from the MIGAL-Galilee Research Institute.
Funding history · 4 rounds · $137.0M total
2022-01
Series B
$111.0M
2020-08
Series A
$18.0M
2019-06
Seed
Undisclosed
2016-07
Undisclosed
Undisclosed
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
biotechnologybiopharmaceuticallife-sciencesgenetic-engineeringmedical-technologiescancer-therapyhospitalshealthcare-providersoncologycell-therapycancer